Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.’
REYKJAVIK, Iceland and PARSIPPANY, N.J. May 21, 2024 ’ In a significant advancement for the treatment of several chronic inflammatory conditions, Teva Pharmaceuticals, a pivotal U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), in collaboration with Alvotech (NASDAQ: ALVO), announced today the commercial availability of SIMLANDI (adalimumab-ryvk) injection in the United States. This noteworthy launch solidifies SIMLANDI as an interchangeable biosimilar to the widely-prescribed biologic medication, Humira.
SIMLANDI, as a therapeutic agent, is designed to address an extensive array of inflammatory diseases, thereby offering new hope and improved quality of life for numerous patients. The specific conditions treated by SIMLANDI include:
- ’Adult Rheumatoid Arthritis’: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- ’Juvenile Idiopathic Arthritis’: The most common type of arthritis in children under 16, characterized by persistent joint swelling, pain, and stiffness.
- ’Adult Psoriatic Arthritis’: A form of arthritis that affects some people who have psoriasis, marked by red patches of skin topped with silvery scales.
- ’Adult Ankylosing Spondylitis’: An inflammatory disease that can cause some of the vertebrae in the spine to fuse.
- ’Crohn’s Disease’: A type of inflammatory bowel disease that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
- ’Adult Ulcerative Colitis’: A chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores.
- ’Adult Plaque Psoriasis’: A skin disease characterized by red patches covered with a silvery white build-up of dead skin cells.
- ’Adult Hidradenitis Suppurativa’: A painful, long-term skin condition causing abscesses and scarring on the skin.
- ’Adult Uveitis’: An inflammation of the middle layer of the eye, which includes the iris, ciliary body, and choroid.
The advent of SIMLANDI as an interchangeable biosimilar is monumental, providing both patients and healthcare providers with an effective and potentially lower-cost alternative to Humira. This aligns with broader efforts within the pharmaceutical industry to enhance accessibility and affordability of vital medications.
Bob Hershberg, CEO of Teva Pharmaceuticals, underscored the potential impact of this launch: Introducing SIMLANDI marks a significant milestone in our commitment to ensuring patients have access to necessary treatments. As an interchangeable biosimilar, SIMLANDI has the potential to not only improve patient outcomes but also significantly reduce healthcare costs.
Echoing this sentiment, Robert Wessman, CEO of Alvotech, stated, Our collaboration with Teva Pharmaceuticals supports our shared vision of delivering biologic treatments that improve patient access to high-quality, affordable medication. The availability of SIMLANDI is a testament to our dedication to this mission.
As SIMLANDI becomes available in the U.S market, its introduction is expected to make a meaningful difference in the therapeutic landscape for patients suffering from chronic inflammatory diseases. With this launch, Teva Pharmaceuticals and Alvotech continue to champion advancements in biosimilar medications, fostering innovation and broadening treatment options for patients globally.
Comments